|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Drug Discovery Partnership: October2010 |
|||
|
Conference Details: |
||||
|
Opal Events is proud to present our next exciting conference Drug Discovery Partnership: Filling the Pipeline. Early stage drug discovery is a key bottleneck in the pipeline to find novel drugs. With key products suffering patent expiration in coming years, the need for new approaches to accelerate development of new chemical entities to treat severely unmet medical needs is more urgent than ever. This drug discovery conference brings together pharmaceutical companies, small biotechnology enterprises, government agencies, for-profit and not-for profit research institutions to exchange ideas, make connections and discuss opportunities to create an environment that will foster pharmaceutical innovation. |
Conference Registration Prices: If you are interested in sponsorship, exhibiting or speaking opportunities, please contact April Stanford at astanford@opalevents.org or 212 532-9898, extension 230. |
|||
| Keynote Luncheon Speaker: | ||||
|
• Dr. Solomon Nwaka, Leader, Lead Discovery for Drugs for Infectious Tropical Diseases, World Health Organization (WHO) |
||||
|
Conference Chairperson: |
||||
|
• Dr. Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford |
||||
|
Conference Co-Chairperson: |
||||
|
• Dr. Jacqueline Hunter, SVP Science Environment Development, GlaxoSmithKline |
||||
|
Our Distinguished Speaker Faculty Includes: |
||||
| • Adam Renslo, Ph.D., Associate Director, Chemistry, Adjunct Assistant Professor of Pharmaceutical Chemistry, University of California, San Francisco • Dr. Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford • Claire T. Driscoll, Director, Technology Transfer Office, National Human Genome Research Institute (NHGRI), National Institutes of Health • Damian O’Connell, MD, Ph.D., VP, Clinical Research Head for the Indications Discovery Unit (IDU), Pfizer; Chairman, Board at Molecular Medicine Ireland • David Brener, Ph.D., Director, Research and Development Alliances, Pfizer Canada • David H. Donabedian, Ph.D., MBA, VP Strategic Alliances, US CEEDD, GlaxoSmithKline • David Schultz, Ph.D., Wistar Scientist, Director, Protein Production, Libraries & Molecular Screening Facility, Wistar Institute • Dutch Chung, Ph.D., J.D., Senior Attorney, Wilson Sonsini Goodrich & Rosati • Dr. Erik M. Schwiebert, Ph.D., CEO, CSO and Director, DiscoveryBioMed, Inc. • Dr. Frederick Monsma, Director, New Lead Discovery, Schering-Plough Research Institute • Gilbert M. Rishton, Ph.D., Scientific Advisory Board, Pyxis Discovery • Giora Feuerstein, M.D., Assistant Vice President, Head, Discovery Translational Medicine, Wyeth Research • Gregory N. Tew, Assistant Professor, Polymer Science and Engineering, University of Massachusetts • Ian Hanegraaff, General Manager, Cybio US Inc. • Dr. Jacqueline Hunter, SVP Science Environment Development, GlaxoSmithKline • Jill O’Donnell-Tormey, Ph.D., Executive Director, Cancer Research Institute • John McGrath, Compound Manager, Broad Institute of Harvard & MIT • Junhu Zhang, President, Tiger Pharmatech • Lars Knutsen, President, Discovery Pharma Consulting LLC • Marcie Glicksman, Ph.D., Sr. Director Leads Discovery and Assistant Professor, Brigham and Women’s Hospital, Harvard Medical School • Mark Parisi, Executive Director, ASINEX Corp. • Melvin Reichman, Ph.D., Director LIMR Chemical Genomics Center (LCGC), Lankenau Institute for Medical Research • Nicola Tolliday, Ph.D., Manager, Screening Outreach, Broad Institute of Harvard & MIT • O. Prem Das, Ph.D., Business Development and Technology Transfer Consultant • PJ. Anand, Executive Vice President, Corporate Development, Arsenal Medical • Reid J. Leonard, Ph.D., Executive Director, Licensing & External Research, Merck Research Laboratories • Dr. Richard Aragon, Program Director, Innovative Molecular Analysis Technologies (IMAT) Program, National Cancer Institute • Richard Davis, Ph.D., Business Development Manager Technology Transfer, Wellcome Trust • Rick Hammar, Director, Compound Management, Chemistry and Screening Services, ASDI Inc. • Sean Ekins, Collaborative Director, Collaborative Drug Discovery • Seth J. Goldenberg, Ph.D. Senior Scientist, Progenra, Inc. • Shawnmarie Mayrand-Chung, Ph.D., J.D., Program Director for the Biomarkers Consortium, Program on Public-Private Partnerships, National Institutes of Health • Dr. Solomon Nwaka, Leader, Lead Discovery for Drugs for Infectious Tropical Diseases, World Health Organization (WHO) • Dr. Thomas Engler, Senior Research Advisor, Discovery Chemistry Research and Technologies, Lilly Research Laboratories, A • Division of Eli Lilly & Co. |
||||
|
Who Will Attend: |
||||
| Pharmaceuticals, Biotech, Academia, Foundation, Technology Companies, and CROs – VP/ Director/ Manager/ Faculty Advisor of: |
||||
| • External Research Collaboration • Scientific Affairs • Business Development • Partnership/ Alliance Management • Office of Technology Transfer • Academic Screening Facilities • School of Medicine/ Life Sciences/ Pharmacy • Grants Manager • Program Office |
• Research & Development • Analytical/ Medicinal Chemistry • Sample/ Compound Management • Assay Development • Lead Discovery/ Optimization • High Throughput Screening (HTS) • Automation • ADMET |
|||
|
Venue Info: |
||||
|
Hyatt Regency Boston |
We are pleased to announce that the Opal room block is open and we are accepting reservations. Please click on the ONLINE HOTEL RESERVATION link below to book your room. The hotel will not accept individual call-ins. |
|||
|
ONLINE HOTEL RESERVATION |
||||
